Search NLS News

Researchers have discovered a variant of the bacteria that causes stomach cancer.

Calluna Pharma has announced the appointments of Mark Gaffney as Chief Executive Officer.

Capitainer has announced that Kristina Thomsen Hall has been appointed as its new Chief Financial Officer (CFO).

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.

BioArctic's partner Eisai has announced that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia.

Through this investment of 12,500 square meters distributed on four levels, the conditions for continued expansion in the coming years are strengthened.


At the beginning of 2024 big financial news was released from the small country of Denmark. It was announced that Novo Holdings would acquire US CDMO Catalent for USD 16.5 billion.

Lundbeck has announced taking one further step in developing treatments for indications in the neuroimmunology and neuroinflammatory space with the initiation of the first clinical trial of its CD40L blocker, Lu AG22515, in patients.

The Company has selected rare disease Idiopathic Pulmonary Fibrosis (IPF) as the initial target indication for novel HDACi CS014.

FinVector’s new production unit is set to become one of the world’s largest facilities for manufacturing gene-therapy treatments.